170 related articles for article (PubMed ID: 21808135)
21. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
[TBL] [Abstract][Full Text] [Related]
22. Expression of Fas and Fas ligand in primary cutaneous squamous cell carcinoma in association with grade of tumor differentiation.
Lee YB; Kyung Kim E; Park HJ; Cho BK; Park YM; Kim JW; Yoo NJ; Park YG; Oh ST
Int J Dermatol; 2013 Sep; 52(9):1092-7. PubMed ID: 23045958
[TBL] [Abstract][Full Text] [Related]
23. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
24. Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.
El-Sarha AI; Magour GM; Zaki SM; El-Sammak MY
Pathol Oncol Res; 2009 Jun; 15(2):241-50. PubMed ID: 19015953
[TBL] [Abstract][Full Text] [Related]
25. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
[TBL] [Abstract][Full Text] [Related]
26. Fas ligand is expressed in normal skin and in some cutaneous malignancies.
Lee SH; Jang JJ; Lee JY; Kim SY; Park WS; Shin MS; Dong SM; Na EY; Kim KM; Kim CS; Kim SH; Yoo NJ
Br J Dermatol; 1998 Aug; 139(2):186-91. PubMed ID: 9767230
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms in FAS (CD95) and FAS ligand (CD178) promoters and risk of tobacco-related oral carcinoma: gene-gene interactions in high-risk Indians.
Karimi MY; Kapoor V; Sharma SC; Das SN
Cancer Invest; 2013 Jan; 31(1):1-6. PubMed ID: 23153021
[TBL] [Abstract][Full Text] [Related]
28. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
Sjöström-Mattson J; Von Boguslawski K; Bengtsson NO; Mjaaland I; Salmenkivi K; Blomqvist C
Acta Oncol; 2009; 48(8):1137-43. PubMed ID: 19863221
[TBL] [Abstract][Full Text] [Related]
29. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
30. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
Younes M; Schwartz MR; Ertan A; Finnie D; Younes A
Cancer; 2000 Feb; 88(3):524-8. PubMed ID: 10649242
[TBL] [Abstract][Full Text] [Related]
31. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
[TBL] [Abstract][Full Text] [Related]
32. Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
Botti C; Buglioni S; Benevolo M; Giannarelli D; Papaldo P; Cognetti F; Vici P; Di Filippo F; Del Nonno F; Venanzi FM; Natali PG; Mottolese M
Clin Cancer Res; 2004 Feb; 10(4):1360-5. PubMed ID: 14977837
[TBL] [Abstract][Full Text] [Related]
33. [Expression of Fas, Fas ligand, Fas-associated death domain protein, caspase 8 and mutant P53 protein in esophageal squamous cell carcinoma].
Xue LY; Ren LQ; Luo W; Guan XJ; Zou SM; Zheng S; Bi R; Xie YQ; He ZG; Lü N
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):150-4. PubMed ID: 17425843
[TBL] [Abstract][Full Text] [Related]
34. Fas ligand upregulation is an early event in colonic carcinogenesis.
Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F
J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113
[TBL] [Abstract][Full Text] [Related]
35. Transitional cell carcinoma expresses high levels of Fas ligand in vivo.
Lee SH; Lee JY; Park WS; Kim SY; Jang JJ; Yoo NJ
BJU Int; 1999 Apr; 83(6):698-702. PubMed ID: 10233582
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.
Daripally S; Nallapalle SR; Katta S; Prasad VV
Tumour Biol; 2015 Sep; 36(10):7817-30. PubMed ID: 25944167
[TBL] [Abstract][Full Text] [Related]
37. [Effect of Slit-Robo signal on apoptosis of oral cancer cell line Tb].
Ma YG; Wang LJ; Han B; Zhang J
Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Apr; 41(4):232-5. PubMed ID: 16784591
[TBL] [Abstract][Full Text] [Related]
38. Fas/FasL pathway and cytokines in keratinocytes in atopic dermatitis - Manipulation by the electromagnetic field.
Szymanski L; Cios A; Lewicki S; Szymanski P; Stankiewicz W
PLoS One; 2018; 13(10):e0205103. PubMed ID: 30286163
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma.
Lerma E; Romero M; Gallardo A; Pons C; Muñoz J; Fuentes J; Lloveras B; Catasus L; Prat J
Virchows Arch; 2008 Jan; 452(1):65-74. PubMed ID: 18000680
[TBL] [Abstract][Full Text] [Related]
40. Correlation of Fas/FasL expression to cell apoptosis in Epstein-Barr virus-associated gastric carcinoma.
He D; Xiao L; Chen JN; Liang Q; Shao CK
Chin J Cancer; 2010 Mar; 29(3):283-7. PubMed ID: 20193111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
